Biogen (MA, USA) and Eisai Co. (Tokyo, Japan) have announced plans to pursue regulatory approval…
Four studies presented at SfN Neuroscience have demonstrated how the microbiome interacts with the brain in mice, revealing the possible mechanisms behind gut–brain communication.
SfN19: Metabolic disturbances in the brain may exacerbate and forewarn Alzheimer’s pathology in mice
Abstracts presented at SfN Neuroscience 2019 have revealed that metabolic disturbances in the brain could exacerbate and forewarn Alzheimer’s pathology in mice.
Researchers have discovered that more women and less men are diagnosed with amnestic mild cognitive impairment when sex-specific scores are used.
What are the main challenges surrounding primary prevention trials for Alzheimer’s? Should researchers be exploring alternative avenues to amyloid-β in these trials? Take a look at our interview with Randall Bateman to find out more.
In this written ‘Ask the Experts’ column, we bring together leaders from our partnered organizations (Alzheimer’s Research UK, Alzheimer’s Society and the UK DRI) to discuss what the future of dementia research might hold.
The Insight 46 study has indicated that changes in blood pressure in people as young as 36 may be linked to poorer brain health later in life.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
A blood test to diagnose individuals at risk of developing Alzheimer’s disease before symptoms arise may be closer to reality, as researchers report a 94% accuracy in recent findings.